Foreign companies file 337 investigation applications for specific antibody conjugated drugs, their components, and downstream products

On November 18, 2025, Abb Vie Inc., ImmunoGen, Inc., and ImmunoGen Switzerland GmbH filed an application with the U.S. International Trade Commission under Section 337 of the U.S. Tariff Act of 1930, claiming that the export, import, and sale of certain antibody conjugate drugs, their components, and downstream products (Certain Antibody Drug Conjugates and Components There of and Products Containing the Same) to the United States violated U.S. Section 337.

Profound Bio US Co. of Seattle, WA, Jiangsu Profound Bio (Suzhou) Co., Ltd. of China, Genmab A/S of Denmark, Genmab B.V. of Netherlands, and Genmab US, Inc. of Plainsboro, NJ are listed as defendants.